辉瑞制药公司 (PFE.US) 2025年第三季度业绩电话会
文章语言：
简
繁
EN
Share
Minutes
原文
会议摘要
Pfizer reported Q3 2025 revenues of $16.7 billion with a 7% operational decrease, mainly due to reduced COVID-19 demand, yet non-COVID products grew 4% operationally. Adjusted EPS was $0.87, exceeding expectations, driven by cost management and gross margin improvements. Highlights included U.S. government agreement for domestic manufacturing investment, strategic acquisition of Medifast for obesity treatment market, and positive clinical trial data for lung and prostate cancer treatments. Pfizer also emphasized vaccine portfolio growth, particularly Prevnar 20, and committed to dividend growth alongside R&D and business development investments. Guidance for 2026, considering Medifast and Three S Bio acquisitions, is to be provided by year-end, reflecting Pfizer's resilience, strategic focus, and dedication to innovation and long-term value creation.
会议速览
Pfizer's Q3 2025 Earnings Call Highlights and Financial OutlookA Pfizer executive welcomes participants to the company's third quarter 2025 earnings call, emphasizing the availability of the call recording and press release on the Pfizer website. The call includes forward-looking statements and non-GAAP financial measures, with reminders about the risks associated. The executive introduces the CEO and CFO who will share prepared remarks, followed by a Q&A session with the leadership team.
Pfizer's Strategic Growth: Acquisitions, Pipeline Progress, and Regulatory MilestonesThe dialogue highlights Pfizer's strategic acquisitions, including the proposed acquisition of Matera, and progress in its R&D pipeline, such as the licensing agreement with Lys Buyer and advancements in cancer immunotherapy. Key regulatory milestones, including FDA updates on sickle cell disease and the US Government agreement, are discussed, showcasing Pfizer's commitment to innovation and patient value.
Pfizer's Q3 2023: Strong Global Growth, Enhanced Vaccines, and Strategic PrioritiesPfizer reported a 7% YoY global operational growth for its Wintle family, with significant gains in international markets. The company achieved 22% YoY growth globally, led by robust demand, diagnostic efforts, and favorable affordability. Notable progress was made in vaccines, with 17% YoY international growth and a focus on next-generation PCV programs. Pfizer maintained leadership in pneumococcal vaccines and BSBA, despite challenges in RSV. The company raised adjusted diluted EPS guidance for 2023, emphasizing strategic priorities and long-term value creation.
Strong Financial Performance Despite Paxlovid Decline, Highlighting Strategic Priorities and Enhanced EfficiencySolid financial performance reflects disciplined execution of strategic priorities, with operational efficiency improvements and strong non-COVID portfolio growth. Despite a 7% revenue decrease driven by reduced Paxlovid demand, the company's non-COVID performance grew 4%, contributing to robust operating margins and improved cash flow expectations. Cost management and a refined commercial strategy are emphasized, focusing on key products and markets, and optimizing global commercial resources. Adjusted earnings per share exceeded expectations, underscoring the company's commitment to long-term shareholder value creation.
Pfizer's Q3 Financials: Revenue, Cost Savings, and Capital AllocationPfizer reported $7.3 billion in revenue from new products, with a 9% growth. The company achieved a 76% adjusted gross margin, driven by product mix and cost management. Pfizer expects $1.5 billion in savings from its Manufacturing Optimization program and $4.5 billion from cost realignment by 2027. Capital allocation includes $7.3 billion in shareholder returns, $7.2 billion in R&D, and a $4.9 billion acquisition of MetSerra, with plans to manage leverage and support future growth.
2025 Financial Guidance Update: Lowering COVID Impact, Strengthening InnovationThe company updates its 2025 financial guidance, reflecting lower COVID-19 product revenues but anticipating strong non-COVID product performance. It outlines a commitment to innovation, cost efficiency, and strategic capital deployment, aiming to deliver new medicines and enhance shareholder value. A new agreement with the U.S. government supports these goals, ensuring clarity for future investments and patient affordability. The guidance for 2026 will likely be provided by year-end.
Analysis of Commercial Performance, Market Share, and Upcoming Indication ImpactDiscussion covers recent commercial performance, competitive dynamics, pricing, and market share in the sector, with inquiries about future indications' potential to boost uptake.
Performance Review of Vida, Pat Se, and Mibc: Market Dynamics and Future ProjectionsDiscussed Vida's strong market share and first-line leadership despite competition, noting gross-to-net headwinds impacting net sales. Highlighted Pat Se's market share potential and growth post-integration adjustments. Anticipated Mibc's expanded patient reach due to ongoing trials, focusing on market dynamics and future growth.
Legal Process and Antitrust Concerns Surrounding a MergerThe dialogue discusses the legal process ahead concerning a merger, emphasizing the argument that the acquisition could be anticompetitive. The speaker outlines the potential issues with the deal, highlighting concerns over market dominance and competitive elimination. Legal resources are being pursued to address these challenges.
Strategic Planning and Financial Guidance for 2026 Amidst Business DevelopmentDiscusses contingency plans for business development, financial guidance for 2026 focusing on Opex with Sara, and potential dilution effects from the NFM deal. Highlights ongoing efforts to identify and acquire innovative medicines globally, emphasizing investments in current and future medicines.
Global Expansion with Focus on China and Advancement in Therapeutic AreasThe dialogue highlights the company's active global presence, particularly in China, with increased team size and efforts. It mentions the strategic importance of a foundational asset across multiple therapeutic areas, promising timely updates on developments.
Prioritizing Manufacturing Investments vs. Cost Efficiencies Under New US AgreementDiscussion revolves around balancing investments in US manufacturing capacity with operational cost efficiencies under a new agreement, emphasizing the strategic deployment of resources to enhance infrastructure while expanding production capabilities.
Factors Behind FTC's Early Deal Clearance HighlightedDiscussion centered on factors supporting an early FTC clearance, emphasizing deal strength, rapid product development, and antitrust considerations, with no surprise expressed over the decision.
Discussion on Magnetism 5 Trial Timing and PCS Lovit Pricing DynamicsThe dialogue covers the delay in the Magnetism 5 trial, attributed to its event-driven nature, and discusses potential differences from a similar trial by another company. It also addresses the increase in R meth price per script, suggesting it may be due to varying channel mixes without significant pricing changes.
Confidence in Ezh 2 Program's Phase 3 Readout and Food Effect Studies in CrpcDiscussion focused on the upcoming phase 3 Ezh 2 readout in Crpc, highlighting confidence in target exposure post-food effect studies and expectations for overall survival, potentially seeing a 20% to 30% benefit, with the first readout expected in the coming months.
Revenue Guidance and Pricing Strategies in the Covid and Obesity Medicine MarketsThe dialogue discusses the company's revenue guidance for the year, considering the potential fluctuations in Covid sales, and the strategic pricing of obesity medications amid market competition.
FDA Alignment and Surrogate Endpoints in 25-Valent Pneumococcal Vaccine TrialsDiscusses delays in pivotal trials for the 25-valent pneumococcal vaccine due to FDA alignment, potential issues with surrogate endpoints, and plans to coordinate pediatric and adult studies. Highlights the vaccine's enhanced immunogenicity against serotype 3 and ongoing research into a 30+ serotype candidate.
Discussion on International Pricing, Reimbursement Hurdles, and Mfn ImpactSpeakers discussed the implications of higher prices on international launches, emphasizing the need for sustainable pricing strategies and potential support from U.S. government trade negotiations. Concerns were raised about reimbursement hurdles and the Mfn impact on revenues, with an expectation for future guidance to clarify quantitative effects.
Discussion on Upcoming Drug Data and In-House Immunology PortfolioThe dialogue covers the evaluation of imminent drug data, including monthly transition, GI tolerability, and combo data, while also discussing an in-house immunology portfolio with five molecules, including a Stat6 inhibitor entering phase 2, and a differentiated portfolio with molecules covering various immune pathways.
Pfizer's Drug Pricing Deal and Mecera Acquisition ControversyDiscussion revolves around Pfizer's unique drug pricing agreement, not shared with competitors, and the acquisition of Mecera amid antitrust concerns, emphasizing the value of assets and competitive advantage in obesity treatment, while addressing the confidentiality and strategic implications of the deal.
Prioritizing Dividend Growth and Deleveraging for Future Share RepurchasesA company discusses its focus on productivity improvements, deleveraging, and maintaining dividend growth. It outlines future investments in key assets and products to offset losses, emphasizing share repurchases as a near-term priority contingent on balance sheet health and business priorities.
Balance Sheet Capacity for Deal Making and Three S Bio's Data ExpectationsDiscussion on available balance sheet capacity for potential deals, emphasizing the need to reserve some for current operations. Also, expectations for data flow from the Three S Bio deal, considering if there will be interim updates or if the first data will be in 2027.
Pfizer's Q3 Update: DD Capacity, Clinical Programs, and Financial MilestonesA Q3 update discusses Pfizer's $13B DD capacity, upcoming phase 3 trials for lung and colorectal cancer, and highlights financial achievements despite low Covid trends.
要点回答
Q：What are the highlights of Pfizer's third quarter 2025 performance?
A：Pfizer's third quarter 2025 performance highlights include executing with discipline and focus on major strategic efforts, agreement with the US Government that provided greater clarity of strategic investment in future innovation and growth, proposed acquisition of Matera, progress since closing the licensing agreement with Lys Buyer, and the continued growth of the R&D pipeline.
Q：How does Pfizer view the potential of the combination with Matera and what is the therapeutic area it aims to impact?
A：Pfizer views the combination with Matera as having substantial value and plans to create value for shareholders and advance innovation to bring important medicines to patients in the high growth therapeutic area of obesity.
Q：What are some of Pfizer's scientific and commercial strengths that are highlighted in the transcript?
A：Pfizer's scientific strengths include deep experience in developing multi-specific antibody therapeutics and unique combination resonances that complement its oncology portfolio. Its commercial strengths include bringing primary care therapies to market, leading clinical, commercial, and strategic momentum with cardiovascular brands, and plans to execute similarly with Matera to invigorate its card-metabolic presence.
Q：What are the outcomes of the Phase 3 huze in combination with Pembrolizumab trial in patients with muscle-invasive cancer?
A：The Phase 3 huze in combination with Pembrolizumab trial demonstrated a 50% reduction in the risk of recurrence and death for patients with muscle-invasive cancer when used before and after standard of care. This made it the first and only adjuvant to improve survival in this population and potentially expand the addressable us population with approximately 18,000 additional patients.
Q：What is the potential impact of the clinical data presentation on brachet and metkovi for patients with non-small cell lung cancer?
A：The clinical data presentation for brachet and metkovi could establish a new benchmark for targeted combination therapies in patients with non-small cell lung cancer harboring a BRAF V600E mutation. This fortifies the strength of Pfizer's growing lung cancer portfolio, which includes small molecules, abiraterone, and 707i-specific therapy.
Q：What were the results from the phase 3 MABR trial evaluating abiraterone in combination with enzalutamide in patients with prostate cancer?
A：The phase 3 MABR trial evaluating abiraterone in combination with enzalutamide showed that it was the first and only AI-based regimen to demonstrate overall survival benefit in patients with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Q：What is the update regarding the FDA's decision on enrollment in Ocribelo studies for sickle cell disease outside of sub-Saharan Africa?
A：The FDA has concluded that Pfizer may resume enrollment of Ocribelo studies outside of sub-Saharan Africa and in individuals who have not relocated from sub-Saharan Africa. Further details on the next steps are still being determined by engaging with regulatory authorities.
Q：How does the Wintle family rank in the oral CGRP class in the US?
A：The Wintle family continues to lead the oral CGRP class in primary care penetration in the US.
Q：What is the year-over-year operational growth for the vaccine portfolio in international markets?
A：The vaccine portfolio achieved 17% year-over-year international operational growth in the quarter.
Q：What is the projected timeline for the next phase 3 PCV program启动，并且数据是否符合预期？
A：The anticipated timeline for the next phase 3 PCV program was delayed due to government bulk order timing. They are planning to start the study next year if the FDA aligns with their approach. They expect fourth dose data from their ongoing phase 1 study early next year. If positive data and regulatory feedback are received, both phase 3 programs could start in 2026, aligning with their strategy to provide a single vaccine across age groups.
Q：What is the growth rate of the BSBP in the 65 plus population in the US and EU?
A：The BSBP achieved 75% year-over-year operational growth in the quarter due to expanded access in key markets.
Q：What is the focus of the company regarding capital allocation and shareholder value?
A：The company's focus is on creating long-term shareholder value by investing in their business for the long term, evidenced by recent business development activities, while also prudently returning capital to shareholders.
Q：What were the revenue and adjusted diluted earnings per share results for the third quarter?
A：Revenues for the third quarter were $16.7 billion, a decrease of 7% operationally versus the same period of the prior year. Adjusted diluted earnings per share was 87 cents ahead of expectations due to overall gross margin and cost management performance.
Q：How are the results of the recently launched and acquired products?
A：Pfizer's recently launched and acquired products delivered $7.3 billion in revenue, growing approximately 9% operationally versus last year.
Q：What were the components contributing to the decrease in adjusted R&D expenses?
A：Adjusted R&D expense decreased 3% operationally, primarily due to a net decrease in spending resulting from a focus on the pipeline and optimization, including the expansion of digital capabilities.
Q：How much did the company invest in R&D and business development in the first nine months of the year?
A：In the first nine months of the year, the company invested $7.2 billion in internal R&D and approximately $1.6 billion in business development activities.
Q：What is the expected impact of the acquisition of Met Serra on the company's 2026 adjusted EPS?
A：The acquisition of Met Serra, with a deal value of approximately $4.9 billion, is expected to be dilutive to 2026 adjusted EPS by an additional 5 cents, on top of the 16 cents dilution already expected from the 3 S Bio deal. However, the company believes both deals will set up a strong potential revenue growth trajectory in 2030 and beyond.
Q：What is the company's position regarding gross leverage and its expectations for the future?
A：Gross leverage at the end of the third quarter was approximately 2.7 times. The company expects the leverage to be above the 2.7 times target after the close of the Met Serra transaction but anticipates bringing it back down to target levels over time.
Q：What was the main driver of the updated full-year 2025 guidance and how does it differ from previous expectations?
A：The updated full-year 2025 guidance was mainly driven by a new volunteering agreement with the US government that ensures patients pay lower prices for tricarbazepine medication. This agreement has no impact on the 2025 guidance but is expected to have a dilutive impact on the 2026 financial outlook.
Q：What factors are influencing the company's adjusted diluted earnings per share guidance for full-year 2025?
A：The adjusted diluted earnings per share guidance for full-year 2025 is being influenced by a more efficient cost structure and stronger performance, resulting in a narrowing of the guidance range to between $3.00 and $3.15 per share.
Q：What is the company's strategy moving forward in terms of enhancing product value and advancing innovation?
A：The company plans to enhance the value of its product portfolio and advance innovation by deploying capital effectively, using digital tools like AI to improve R&D productivity, prioritizing investments in key R&D programs, and driving business development to deliver new growth.
Q：What are the dynamics impacting the quarterly results mentioned in the speech?
A：The quarterly results were impacted by very strong demand growth and continued market share leadership, partially offset by two gross to net headwinds: the impact of IRA manufacturer rebates and payer contracting from the third quarter.
Q：How is competition affecting Trx and first line share?
A：Competition is taking some first line share from treatment naive patients, and so far, Abuja has driven minimal switching to date.
Q：What is the performance and market share of Pat Se?
A：The performance of Pat Se is in line with expectations, with about 55% share among cypt ineligible patients and 45% to 50% share among CISPA and eligible patients.
Q：What was the impact of the integration of Sgen products into the Pfizer portfolio on sales?
A：The integration of Sgen products into the Pfizer portfolio from a drop ship model to a wholesaler model resulted in a one-time growth in Q2 sales. However, as we cycle into Q4, sales are expected to return to growth, adjusted for 2 to 3 weeks of inventory.
Q：What is the plan if M&A for Sarah does not work out, and how should Opex be considered for 2026?
A：The plan if M&A for Sarah does not work out is not specified, but the company continues to work on business development across all therapeutic areas and globally. For 2026, the impact of the recent NFM deal on Opex should be considered with and without the acquisition, and the company will provide guidance by the end of the year.
Q：How are manufacturing investments and operational cost efficiencies prioritized in relation to the Mfn agreement?
A：The company is making strategic investments in the US from a production perspective, working on plans with the new agreement with the US government to deploy capacity and build out manufacturing. They aim to improve manufacturing infrastructure while investing in the US, making sure these efforts are not in conflict.
Q：What factors led to the early termination of the waiting period by the FTC?
A：The FTC made their own decision to early termination of the waiting period, and although they were aware of the questions, they decided that it is appropriate to release the deal, which is now clear.
Q：What does the continued development and potential rapid market introduction of the products signify for patients and shareholders?
A：The continued development and potential for rapid market introduction of the products signify a strong pathway to clearance and the ability to quickly bring products to the market, which is beneficial for patients and shareholders under the company's management and direction.
Q：Why was the Magenta 5 trial delayed and what are the potential differences between the company's trial and J&J's trial?
A：The Magenta 5 trial was delayed possibly due to event-related reasons, and the timing could shift if certain events happen, which are often positive. The potential differences between the company's trial and J&J's trial could be related to how these events unfold in the studies.
Q：What factors could influence the pricing of GLP-1 medicines and how does the company justify the prices it pays to partners like Mecara?
A：Competition is a key factor influencing the pricing of GLP-1 medicines, leading to expected price declines. The company takes this into account in its financial calculations when pricing and evaluating deals like the one with Mecara, considering the potential for future price reductions due to competition.
Q：Why was the initiation of the pivotal trial for the 25-valent pneumococcal program delayed and what is the impact of FDA alignment on the trial?
A：The initiation of the pivotal trial for the 25-valent pneumococcal program was delayed pending positive data and FDA feedback. FDA alignment is crucial for the trial, and the公司在设计研究和选择终点时需与FDA密切合作。 A change in FDA dialogue tone or surrogate endpoints could impact the trial's approval.
Pfizer Inc.
Follow
